antirheumatic agents

Summary

Summary: Drugs that are used to treat RHEUMATOID ARTHRITIS.

Top Publications

  1. pmc EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:964-75. 2010
  2. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
  3. ncbi Rheumatoid arthritis
    David L Scott
    Department of Rheumatology, King s College London School of Medicine, London, UK
    Lancet 376:1094-108. 2010
  4. ncbi Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
    Ronald F van Vollenhoven
    Karolinska Institute, Stockholm
    N Engl J Med 367:508-19. 2012
  5. ncbi Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
    Roy Fleischmann
    Metroplex Clinical Research Center, Dallas, TX 75231, USA
    N Engl J Med 367:495-507. 2012
  6. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
  7. ncbi Rheumatoid arthritis
    Lars Klareskog
    Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
    Lancet 373:659-72. 2009
  8. pmc Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
    G Jones
    Menzies Research Institute, University of Tasmania, Hobart, TAS 7001, Australia
    Ann Rheum Dis 69:88-96. 2010
  9. pmc Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
    Maxime Dougados
    Department of Rheumatology, Cochin Hospital, Paris, France
    Ann Rheum Dis 72:43-50. 2013
  10. ncbi Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
    Joel M Kremer
    Albany Medical College and Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 63:609-21. 2011

Detail Information

Publications329 found, 100 shown here

  1. pmc EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:964-75. 2010
    ....
  2. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
    ..Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA)...
  3. ncbi Rheumatoid arthritis
    David L Scott
    Department of Rheumatology, King s College London School of Medicine, London, UK
    Lancet 376:1094-108. 2010
    ..Infections and high costs restrict prescription of biological agents. Long-term remission induced by intensive, short-term treatment selected by biomarker profiles is the ultimate goal...
  4. ncbi Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
    Ronald F van Vollenhoven
    Karolinska Institute, Stockholm
    N Engl J Med 367:508-19. 2012
    ..Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis...
  5. ncbi Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
    Roy Fleischmann
    Metroplex Clinical Research Center, Dallas, TX 75231, USA
    N Engl J Med 367:495-507. 2012
    ..Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis...
  6. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  7. ncbi Rheumatoid arthritis
    Lars Klareskog
    Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
    Lancet 373:659-72. 2009
    ..Understanding the cause and pathogenesis of different rheumatoid arthritis subsets will lead not only to individualised treatments during early phases of the illness but also, possibly, to disease prevention...
  8. pmc Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
    G Jones
    Menzies Research Institute, University of Tasmania, Hobart, TAS 7001, Australia
    Ann Rheum Dis 69:88-96. 2010
    ..The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis...
  9. pmc Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
    Maxime Dougados
    Department of Rheumatology, Cochin Hospital, Paris, France
    Ann Rheum Dis 72:43-50. 2013
    ..In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy...
  10. ncbi Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
    Joel M Kremer
    Albany Medical College and Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 63:609-21. 2011
    ....
  11. ncbi 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
    Desiree van der Heijde
    Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Ann Rheum Dis 70:905-8. 2011
    ..Sulfasalazine is no longer mandatory in this group of patients. Finally, efficacy should be evaluated after at least 12 weeks. The remaining recommendations stayed largely unchanged...
  12. ncbi American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Correspondence to Maarten Boers, Department of Epidemiology and Biostatistics, VU University Medical Center, PK 6Z 165, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Rheum Dis 70:404-13. 2011
    ..This work was undertaken to develop such a definition...
  13. ncbi State-of-the-art: rheumatoid arthritis
    Iain B McInnes
    Institute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, UK
    Ann Rheum Dis 69:1898-906. 2010
    ..Throughout the review, emphasis is placed on unanswered questions and challenges in this exciting field...
  14. ncbi Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Roy Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 64:617-29. 2012
    ....
  15. ncbi Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial
    Marije F Bakker
    Department of Rheumatology and Clinical Immunology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, and Diakonessenhuis, Utrecht, The Netherlands
    Ann Intern Med 156:329-39. 2012
    ..Treatment strategies for tight control of early rheumatoid arthritis (RA) are highly effective but can be improved...
  16. ncbi Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
    Desiree van der Heijde
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 65:559-70. 2013
    ..Data from a planned 12-month interim analysis are reported...
  17. pmc Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
    Takao Koike
    Hokkaido University Graduate School of Medicine, Hokkaido, Japan
    Ann Rheum Dis 70:2148-51. 2011
    ..An interim analysis of an all-patient postmarketing surveillance programme in Japan to investigate the safety of tocilizumab for the treatment of rheumatoid arthritis (RA) in the real world...
  18. ncbi New therapies for treatment of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 370:1861-74. 2007
    ..Novel therapeutic strategies in conjunction with optimised disease assessment for better treatment of rheumatoid arthritis and an outlook into potential future targets are also presented...
  19. ncbi Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
    Yusuf Yazici
    New York University Hospital for Joint Diseases, New York, USA
    Ann Rheum Dis 71:198-205. 2012
    ..To evaluate efficacy of tocilizumab in US patients with moderate to severe active rheumatoid arthritis (RA) and inadequate clinical response to disease-modifying antirheumatic drugs (DMARD). Safety-related outcomes were also analysed...
  20. pmc Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
    Arthur Kavanaugh
    UCSD, UCSD, Rheumatology, Allergy, Immunology, La Jolla, CA, USA
    Ann Rheum Dis 72:64-71. 2013
    ..2 at weeks 22 and 26) and clinical, radiographic and functional outcomes in methotrexate-naive patients with early rheumatoid arthritis (RA)...
  21. ncbi A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
    P Mease
    Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 71:1183-9. 2012
    ..Interleukin 6 (IL-6) plays a key role in the inflammatory cascade in rheumatoid arthritis. BMS945429 is a humanised, monoclonal antibody that potently binds IL-6...
  22. pmc 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 70:896-904. 2011
    ..There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good...
  23. ncbi Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
    Arthur Kavanaugh
    University of California, San Diego, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 60:976-86. 2009
    ..To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA)...
  24. ncbi Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
    J L Nam
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Ann Rheum Dis 69:976-86. 2010
    ..To review the evidence for the efficacy and safety of biological agents in patients with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the European League Against Rheumatism (EULAR) Task Force...
  25. pmc Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythr
    G Wells
    Department of Epidemiology and Community Medicine, University of Ottawa, Canada
    Ann Rheum Dis 68:954-60. 2009
    ..To validate and compare the definition of the Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to the definition based on erythrocyte sedimentation rate (ESR)...
  26. pmc Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    M Schiff
    Denver Arthritis Clinic, 200 Spruce Street 100, Denver, CO 80230, USA
    Ann Rheum Dis 67:1096-103. 2008
    ..The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197...
  27. pmc Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
    R Westhovens
    UZ Gasthuisberg, Department of Rheumatology, B 3000 Leuven, Belgium
    Ann Rheum Dis 68:1870-7. 2009
    ..To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) and poor prognostic factors...
  28. ncbi Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-bli
    Paul Emery
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, corrected Leeds, UK
    Arthritis Rheum 60:2272-83. 2009
    ..To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis (RA)...
  29. pmc Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
    C Salliot
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 68:1100-4. 2009
    ..To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA)...
  30. pmc American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Boston University School of Medicine, Boston, Massachusetts, USA
    Arthritis Rheum 63:573-86. 2011
    ..This work was undertaken to develop such a definition...
  31. ncbi Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
    Pedro Machado
    Rheumatology Department, Coimbra University Hospital, Coimbra, Portugal
    Ann Rheum Dis 70:47-53. 2011
    ..Criteria for disease activity states and improvement scores are important for use in clinical practice, observational studies and clinical trials and so far have not been developed for the ASDAS...
  32. ncbi Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
    Monika Schoels
    2nd Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 71:1303-8. 2012
    ..Optimal treatment for rheumatoid arthritis (RA) after inadequate response (IR) to tumour necrosis factor α inhibitors (TNFi) remains uncertain...
  33. ncbi Therapies for active rheumatoid arthritis after methotrexate failure
    JAMES R O'DELL
    Veterans Affairs VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE 68105, USA
    N Engl J Med 369:307-18. 2013
    ....
  34. pmc Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
    Yoshiya Tanaka
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu City, Japan
    Ann Rheum Dis 71:817-24. 2012
    ..To assess the efficacy and safety of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA)...
  35. ncbi A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    Joel M Kremer
    Albany Medical College, Albany, New York 12206, USA
    Arthritis Rheum 64:970-81. 2012
    ....
  36. ncbi Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    Cem Gabay
    University Hospitals of Geneva, Geneva, Switzerland
    Lancet 381:1541-50. 2013
    ..We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis...
  37. ncbi A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
    Zoe Ash
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 71:319-26. 2012
    ....
  38. pmc Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    Maya H Buch
    Section of Musculoskeletal Diseases, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 70:909-20. 2011
    ..Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA...
  39. pmc Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
    N Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
    Ann Rheum Dis 68:1580-4. 2009
    ..To evaluate the safety and efficacy of 5-year, long-term tocilizumab monotherapy for patients with rheumatoid arthritis...
  40. pmc Understanding emerging treatment paradigms in rheumatoid arthritis
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Center, C1 39, PO Box 9600, 2300 RC Leiden, The Netherlands
    Arthritis Res Ther 13:S3. 2011
    ..In the present review, we summarize the salient points of several recently proposed and emerging treatment paradigms with an emphasis on how these strategies may impact future practice...
  41. ncbi An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis
    A K Brown
    Leeds Institute of Molecular Medicine, University of Leeds, and Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 58:2958-67. 2008
    ..The purpose of this study was to evaluate the long-term significance of subclinical synovitis and its relationship to structural outcome...
  42. pmc Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
    J J Haringman
    Division of Clinical Immunology and Rheumatology, F4 218, Academic Medical Centre University of Amsterdam, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Ann Rheum Dis 64:834-8. 2005
    ..Previous work identified synovial sublining macrophage numbers as a potential biomarker for clinical efficacy in rheumatoid arthritis...
  43. ncbi Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial
    Björn Svensson
    University of Lund, Lund, Sweden
    Arthritis Rheum 52:3360-70. 2005
    ..To assess the efficacy of low-dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA)...
  44. ncbi Ankylosing spondylitis
    Jurgen Braun
    Ruhr Universitat Bochum, Rheumazentrum Ruhrgebiet, 44652 Herne, Germany
    Lancet 369:1379-90. 2007
    ..The new treatment options with tumour necrosis factor blockers seems a breakthrough for patients refractory to conventional treatment...
  45. ncbi A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    J S Smolen
    University of Vienna and Lainz Hospital, Austria
    Rheumatology (Oxford) 42:244-57. 2003
    ..The objective of this study was to verify the usefulness of a simple disease activity index (SDAI) for rheumatoid arthritis (RA)...
  46. ncbi Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....
  47. ncbi Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    M C Genovese
    Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Ann Rheum Dis 67:547-54. 2008
    ..To evaluate the safety and efficacy of abatacept during 2 years of the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial in patients with rheumatoid arthritis...
  48. ncbi Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 70:39-46. 2011
    ..The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX...
  49. pmc Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy
    Jing Cui
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 62:1849-61. 2010
    ..The aim of the present study was to test established RA genetic risk factors to determine whether the same alleles also influence the response to anti-TNF therapy...
  50. ncbi Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish
    Merete Lund Hetland
    DANBIO Registry, Copenhagen University Hospital, Department of Rheumatology, Hvidovre, Denmark
    Arthritis Rheum 62:22-32. 2010
    ....
  51. pmc Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate
    M C Genovese
    Stanford University, Palo Alto, California 94304, USA
    Arthritis Rheum 63:2854-64. 2011
    ..To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept...
  52. pmc Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, 1367 Washington Ave, Albany, NY 12206, USA
    Ann Rheum Dis 70:1826-30. 2011
    ..To evaluate abatacept treatment over 3 years in patients with rheumatoid arthritis (RA) refractory to methotrexate (MTX)...
  53. pmc Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
    J A P da Silva
    Reumatologia, Hospitais da Universidade, 3000 075 Coimbra, Portugal
    Ann Rheum Dis 65:285-93. 2006
    ..Safety data from recent randomised controlled clinical trials of low dose glucocorticoid treatment in RA suggest that adverse effects associated with this drug are modest, and often not statistically different from those of placebo...
  54. ncbi Granulomatous infectious diseases associated with tumor necrosis factor antagonists
    R S Wallis
    Department of Medicine, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, NJ 07103, USA
    Clin Infect Dis 38:1261-5. 2004
    ..25-fold greater among patients who received infliximab than among those who received etanercept. The clustering of reports shortly after initiation of treatment with infliximab is consistent with reactivation of latent infection...
  55. ncbi Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, 9500 Gilman Drive, Room A 112, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 64:2504-17. 2012
    ..Herein we report 1-year clinical, radiographic, and safety findings...
  56. ncbi Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
    Dora Pascual-Salcedo
    Immunology Unit, Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
    Rheumatology (Oxford) 50:1445-52. 2011
    ..To analyse the clinical relevance of the production of anti-infliximab antibodies (anti-infliximab Abs) in patients with RA undergoing infliximab treatment over a prolonged period of time...
  57. pmc Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study
    Michael E Weinblatt
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 65:28-38. 2013
    ..Therefore, this study was undertaken as the first head-to-head comparison of subcutaneous (SC) abatacept and SC adalimumab, both administered along with background methotrexate (MTX), for the treatment of RA...
  58. ncbi Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort
    Mohammed Z Cader
    Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
    Ann Rheum Dis 70:949-55. 2011
    ..This study therefore assesses the performance of these new criteria in patients with early synovitis...
  59. ncbi In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
    Hamed Rezaei
    Unit of Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:186-91. 2012
    ..To investigate the 2-year clinical and radiological outcomes of patients with early rheumatoid arthritis (RA; symptom duration <1 year) who had initially responded well to methotrexate monotherapy...
  60. ncbi Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria
    M P M van der Linden
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 63:37-42. 2011
    ....
  61. ncbi An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    Arthritis Rheum 63:337-45. 2011
    ..To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies...
  62. ncbi The need for personalised medicine for rheumatoid arthritis
    John D Isaacs
    Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University, Newcastle, UK
    Ann Rheum Dis 70:4-7. 2011
    ....
  63. ncbi Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
    Katerina Chatzidionysiou
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 70:1575-80. 2011
    ..To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response...
  64. pmc Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
    G R Burmester
    Charite University Medicine Berlin, Free University and Humboldt University of Berlin, 10117 Berlin, Germany
    Ann Rheum Dis 68:1863-9. 2009
    ..To assess the safety of adalimumab in rheumatoid arthritis (RA) over time and across five other immune-mediated inflammatory diseases and to compare adalimumab malignancy and mortality rates with data on the general population...
  65. pmc Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
    P Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds corrected
    Ann Rheum Dis 69:510-6. 2010
    ..Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA...
  66. ncbi Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
    Geertje M Bartelds
    Jan van Breemen Research Institute, Amsterdam, The Netherlands
    JAMA 305:1460-8. 2011
    ..Little is known about the clinical relevance of antidrug antibodies against these drugs during long-term follow-up...
  67. pmc Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
    W G Dixon
    ARC Epidemiology Unit, University of Manchester, Manchester M13 9PT, UK
    Ann Rheum Dis 69:522-8. 2010
    ....
  68. pmc EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    B Combe
    Immuno Rhumatologie, Lapeyronie Hosp, Montpellier, France
    Ann Rheum Dis 66:34-45. 2007
    ..To formulate EULAR recommendations for the management of early arthritis...
  69. pmc Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
    Andrea Rubbert-Roth
    Department of Internal Medicine, University of Cologne, Cologne, Germany
    Rheumatology (Oxford) 49:1683-93. 2010
    ..To evaluate the efficacy and safety of three dosing and repeat treatment regimens of rituximab (RTX) plus MTX in patients with active RA...
  70. ncbi Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
    E Keystone
    Division of Rheumatology, University of Toronto, Toronto, Canada
    Ann Rheum Dis 68:216-21. 2009
    ..To determine if treatment with a B cell-targeted therapy can inhibit the progression of structural joint damage in patients with rheumatoid arthritis (RA), exhibiting an inadequate response to tumour necrosis factor (TNF) inhibitors...
  71. pmc Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
    Monika Schoels
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:638-43. 2010
    ..To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment...
  72. pmc Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
    Hisashi Yamanaka
    Institute of Rheumatology, Tokyo Women s Medical University, 10 22 Kawada cho, Shinjuku ku, Tokyo, 162 0054, Japan
    Mod Rheumatol 21:122-33. 2011
    ..Tocilizumab infusion is therefore applicable not only as an alternative approach for anti-TNF therapy-resistant patients, but also as primary biologic therapy for active RA patients...
  73. ncbi Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons
    Jeroen P Jansen
    Mapi Values Ltd, Boston, MA 02108, USA
    Value Health 11:956-64. 2008
    ..Next, the Bayesian MTC for continuous outcomes are presented. We finish with a discussion of how MTC can best be presented in order to maximize acceptance by target audiences, i.e., clinicians and market access decision-makers...
  74. pmc Treatment recommendations for psoriatic arthritis
    C T Ritchlin
    Clinical Immunology Research Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, New York 14642, USA
    Ann Rheum Dis 68:1387-94. 2009
    ..To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion...
  75. pmc Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Effi
    P Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds corrected
    Ann Rheum Dis 69:1629-35. 2010
    ..This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment...
  76. ncbi ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
    D van der Heijde
    Department of Rheumatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    Ann Rheum Dis 68:1811-8. 2009
    ....
  77. pmc Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis
    Chunyu Liu
    Biogen Idec Inc, Cambridge, Massachusetts, USA
    Mol Med 14:575-81. 2008
    ..Replications of these results in independent and larger data sets clearly are required. We provide a reference list of candidate SNPs (P < 0.01) that can be investigated in future pharmacogenomic studies...
  78. ncbi Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    Lars Klareskog
    Rheumatology Unit, Department of Medicine, Karolinska Institute Karolinska Hospital, Stockholm 17176, Sweden
    Lancet 363:675-81. 2004
    ..We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis...
  79. ncbi Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
    W G Dixon
    British Society for Rheumatology Biologics Register Control Centre Consortium, Manchester, UK
    Arthritis Rheum 54:2368-76. 2006
    ....
  80. ncbi Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept
    D van der Heijde
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 58:1324-31. 2008
    ..To investigate the effect of etanercept therapy on radiographic progression in patients with ankylosing spondylitis (AS)...
  81. ncbi Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    Arthritis Rheum 58:2968-80. 2008
    ..To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with conventional disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis (RA)...
  82. pmc Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emph
    James B Galloway
    Arthritis Research UK Epidemiology Unit, The University of Manchester, Department of Infectious Diseases, North Manchester General Hospital, Stopford Building, Oxford Road, Manchester M13 9PT, UK
    Rheumatology (Oxford) 50:124-31. 2011
    ..To evaluate the risk of serious infections (SIs) in patients with RA treated with anti-TNF therapy with emphasis on the risk across different ages...
  83. doi American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008
  84. pmc IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    P Emery
    Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:1516-23. 2008
    ..The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy...
  85. ncbi The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis
    Marco Gattorno
    G Gaslini Institute, Genoa, Italy
    Arthritis Rheum 58:1505-15. 2008
    ..To assess the clinical response to interleukin-1 (IL-1) blockade and in vitro IL-1beta and IL-18 secretion in patients with systemic-onset juvenile idiopathic arthritis (JIA)...
  86. ncbi Utility of animal models for identification of potential therapeutics for rheumatoid arthritis
    M Hegen
    Inflammation Discovery Research, Wyeth Research, Cambridge, MA 02140 2311, USA
    Ann Rheum Dis 67:1505-15. 2008
    ....
  87. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  88. ncbi An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:1303-12. 2010
    ..The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy...
  89. ncbi Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab
    C Gonzalez-Juanatey
    Cardiology, Hospital Xeral Calde, Lugo, Spain
    Clin Exp Rheumatol 24:309-12. 2006
    ..In this study we aimed to assess whether adalimumab, a fully human monoclonal antibody directed against TNF-alpha, was able to improve endothelial function in RA patients with long-standing disease refractory to infliximab...
  90. ncbi Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France
    T Lequerre
    Rheumatology Department, Rouen University Hospital and Inserm 905, 76031 Rouen, France
    Ann Rheum Dis 67:302-8. 2008
    ..Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD)...
  91. pmc Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor
    Iris Navarro-Millan
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Clin Ther 34:788-802.e3. 2012
    ....
  92. ncbi Biologics-based therapy for the treatment of rheumatoid arthritis
    D L Scott
    Department of Rheumatology, King s College London School of Medicine, Weston Education Centre, London, UK
    Clin Pharmacol Ther 91:30-43. 2012
    ..They are mainly coadministered with disease-modifying drugs such as methotrexate when the latter are found to achieve insufficient disease control on their own...
  93. pmc Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 71:687-93. 2012
    ..Such disassociation of disease activity and structural damage has not been shown for biological agents other than TNF-i...
  94. ncbi Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons
    Niels Graudal
    Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Arthritis Rheum 62:2852-63. 2010
    ..To define the differences in effects on joint destruction in rheumatoid arthritis (RA) patients between therapy with single and combination disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, and biologic agents...
  95. ncbi Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria
    Yuko Kaneko
    Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
    Rheumatology (Oxford) 50:1268-74. 2011
    ..To validate the sensitivity and specificity of the 2010 RA classification criteria...
  96. ncbi Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden
    Lancet 379:1712-20. 2012
    ..Here we report the 2 year follow-up assessment...
  97. ncbi Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study
    N B Klarenbeek
    Leiden University Medical Center, Leiden, The Netherlands
    Ann Rheum Dis 70:315-9. 2011
    ..To determine the relapse rate after discontinuing treatment in patients with rheumatoid arthritis (RA) in sustained clinical remission, to identify predictors of a relapse and to evaluate treatment response after restarting treatment...
  98. ncbi Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
    Henrik Christian Leffers
    Department of Rheumatology, Copenhagen University Hospital Glostrup, Glostrup, Denmark
    Ann Rheum Dis 70:1216-22. 2011
    ....
  99. ncbi Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update
    Jasvinder A Singh
    Medicine and Epidemiology, Division of Clinical Immunology Rheumatology, University of Alabama, Birmingham, AL 35294 USA
    J Manag Care Pharm 18:S1-18. 2012
    ..The report reveals there is still much research to be done concerning the side effects of these agents and their influence in different patient subgroups...
  100. ncbi Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
    Jeffrey D Greenberg
    Department of Rheumatology, New York University Hospital for Joint Diseases, 301 East 17th Street, Suite 1410, New York, NY 10003, USA
    Ann Rheum Dis 70:576-82. 2011
    ..To examine the association of cardiovascular events with tumour necrosis factor (TNF) α antagonist use compared with non-biological disease-modifying antirheumatic drug (DMARD) utilisation in patients with rheumatoid arthritis (RA)...
  101. pmc Time to achieve remission determines time to be in remission
    Lydia G Schipper
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6500 HB, The Netherlands
    Arthritis Res Ther 12:R97. 2010
    ..The aim was to study the association between time-to-remission and sustainability of remission in a cohort of early RA patients treated according to daily practice...

Research Grants66

  1. Pharmacology of Antirheumatic Drugs
    Bruce Cronstein; Fiscal Year: 2007
    ..abstract_text> ..
  2. High Throughput Screen for Novel Anti-Rheumatic Compounds
    Dale J Christensen; Fiscal Year: 2010
    ..In this we propose to develop assays that will help to identify these novel drug leads that can be used to develop a new anti-RA therapy. ..
  3. Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.
    SEOYOUNG CATHERINE KIM; Fiscal Year: 2013
    ..Both Divisions have valuable resources including space, equipment, and knowledgeable faculty including experts in RA research as well as pharmacoepidemiology to help me achieve my goals. ..
  4. Developing Small MIF Inhibitors for Rheumatoid Arthritis
    Christian Grant; Fiscal Year: 2013
    ..Dose finding studies and PK profiling will first be performed with a preference for oral dosing. An optimized dose and route of administration will then be chosen to test the therapeutic efficacy of two lead compounds in the RA models ..
  5. Modifiable Disparities in Treatment for Rheumatoid Arthritis
    DANIEL HAL SOLOMON; Fiscal Year: 2012
    ..abstract_text> ..
  6. Vanderbilt Multidisciplinary Clinical Research Center
    Charles M Stein; Fiscal Year: 2012
    ..The VMCRC is situated in an environment that provides an extraordinarily rich research base as well as outstanding institutional resources and a commitment to clinical research that will facilitate success of the Center. ..
  7. 99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis
    John A Zebala; Fiscal Year: 2011
    ..The proposed RadioDAP technology will be used to simultaneously improve RA therapy and diagnosis. ..
  8. Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment
    Duane D Miller; Fiscal Year: 2013
    ..Success in developing such agents will not only have high impact for RA, but will also have significant impact in treating many other autoimmune diseases. ..
  9. Central Pain Mechanisms, Pain Intensity and Drug Response in Rheumatoid Arthritis
    YVONNE CLAIRE LEE; Fiscal Year: 2013
    ..The results of this study will have an important positive impact by identifying mechanism-based targets for pain management in systemic inflammatory diseases. ..
  10. Genetic predictors of response to anti-TNF therapy in rheumatoid arthritis
    Soumya Raychaudhuri; Fiscal Year: 2013
    ..In theory, identifying specific pieces of DNA ("alleles") that predict treatment response should aid in targeting therapy to the right individuals early in the course of disease before bone destruction occurs. ..
  11. Treatment of Early Aggressive Rheumatoid Arthritis TEAR
    Larry Moreland; Fiscal Year: 2001
    ....
  12. RHEUMATIC DISEASES CORE CENTER
    Gregg Silverman; Fiscal Year: 2006
    ..An Administrative Core (PI-G.J. Silverman, Center Director) will provide overall direction and supervision to all Center programs through an Executive Committee, which will be assisted by an Outside Advisory Committee. ..
  13. CII ORAL TOLERANCE INDUCTION IN RA PATIENTS OFF NSAIDS
    Arnold Postlethwaite; Fiscal Year: 2001
    ..In summary, by withdrawing NSAIDs, which interfere with oral tolerance induction, from RA patients we believe this study will fully explore the therapeutic potential of oral CII tolerance induction in RA. ..
  14. Predictors of Treatment Response in Early Aggressive RA
    S Bridges; Fiscal Year: 2007
    ..abstract_text> ..
  15. PEMF Efficacy in Reducing Rheumatoid Arthritis Symptoms
    Cheryl Bourguignon; Fiscal Year: 2005
    ..Women in the active and sham PEMF groups will also record their daily intervention use. Descriptive statistics and mixed effects models will be used to conduct the analysis of the aims. ..
  16. Abatacept Vs TNF Blockade in Early Rheumatoid Arthritis
    EUGENE ST CLAIR; Fiscal Year: 2007
    ..The proposed clinical trial will compare the remission-inducing capabilities of two novel therapies for early RA, and search for biomarkers that predict treatment response. [unreadable] [unreadable] [unreadable] [unreadable]..
  17. Macromolecular Therapy for Improved Treatment of Rheumatoid Arthritis
    Dong Wang; Fiscal Year: 2009
    ..Eventually, this novel delivery system would lead to improved efficacy and safety profiles for treatment of rheumatoid arthritis and other inflammatory joint disorders. ..
  18. MKP-1 IN Regulation of Inflammatory Cytokine Production
    Yusen Liu; Fiscal Year: 2004
    ....
  19. IKKi expression and regulation in rheumatoid arthritis
    Gary Firestein; Fiscal Year: 2005
    ..We propose to test the hypothesis that IKKi is an important signal transduction pathway that regulates inflammation in chronic arthritis and is a novel target for development of anti-rheumatic agents. ..
  20. Rheumatoid Arthritis Induction Trial (RAITMAT)
    Larry Moreland; Fiscal Year: 2007
    ..This will lead to the development of the proposed Rheumatoid Arthritis Induction Trial with MTX and Anti-TNF Therapy (RAITMAT). [unreadable] [unreadable] [unreadable] [unreadable]..
  21. Lymphoma in Autoimmune Disease: Consequence of Immune Suppression or Stimulation?
    Sasha Bernatsky; Fiscal Year: 2008
    ..Our proposed project will help identify patients at highest risk for lymphoma and provide guidance regarding initiation and maintenance of therapy to control SLE. [unreadable] [unreadable] [unreadable]..
  22. CLINICAL RESEARCH TRAINING PROGRAM
    Larry Moreland; Fiscal Year: 2004
    ..abstract_text> ..
  23. ANDROGEN AS ADJUNCT THERAPY IN RHEUMATOID ARTHRITIS
    John Davis; Fiscal Year: 2002
    ..abstract_text> ..
  24. CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGY
    Daniel Lovell; Fiscal Year: 2004
    ..2. Determine the long-term efficacy and safety of these treatment regimens in sJRA. ..
  25. AUTOIMMUNITY AND CONNECTIVE TISSUE BIOLOGY TRAINING
    William Rigby; Fiscal Year: 2008
    ..These forums facilitate the high level of faculty-student interaction that is traditional at Dartmouth and results in the recognition of our research efforts at both the national and international level. [unreadable] [unreadable]..
  26. Novel Targets of the Von Hippel Lindau Gene
    William Rigby; Fiscal Year: 2006
    ..We hypothesize that the absence of pVHL results in the activation of the p38 SAPK pathway and hnRNP A2 overexpression and propose to address this and its relevance to GLUT1 mRNA turnover. ..
  27. REGULATION OF CD154 EXPRESSION
    WILLIAM FREDERICK CARSON RIGBY; Fiscal Year: 2010
    ..Importantly, the CD153'UTR CA repeats are polymorphic with certain alleles associated with CD154 overexpression and the development of RA and SLE. ..
  28. Rheumatoid Arthritis: Predictors of Therapeutic Response
    JAMES O DELL; Fiscal Year: 2002
    ..Retrospective analysis of this information can be utilized to plan prospective clinical trials using potentially predictive patterns of cytokine, matrix metalloproteinases, and genetic factors. ..
  29. Regulation of CD154 gene expression in vivo
    William Rigby; Fiscal Year: 2002
    ..As a result, we will create a model system with which to study its unique regulation and possibly develop novel approaches to regulating its biosynthesis. ..
  30. Osteoporosis in Women with Rheumatoid Arthritis
    Daniel Solomon; Fiscal Year: 2006
    ..This epidemiologic data will inform future trials of osteoporosis treatments among patients with RA. As well, the study cohort will comprise one of the largest RA registries with an explicit plan to examine osteoporosis. ..
  31. Micellar VIP Nanoparticles for Rheumatoid Arthritis
    Israel Rubinstein; Fiscal Year: 2007
    ..abstract_text> ..
  32. The vital role of BAFF in the development of SLE
    William Stohl; Fiscal Year: 2010
    ..abstract_text> ..
  33. Henoch Schonlein Purpura and Corticosteroid Treatment
    PAMELA WEISS; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  34. The impact of the pneumococcal conjugate vaccine on pneumonia hospitalizations
    CARLOS GRIJALVA; Fiscal Year: 2008
    ..We propose the use of NIS and SID for the evaluation of the pneumococcal conjugate vaccination program, using an innovative approach. [unreadable] [unreadable] [unreadable] [unreadable]..
  35. RA Comorbidity Bone Health in Men and African Americans
    Ted Mikuls; Fiscal Year: 2008
    ..Mikuls' continued development as an independent clinical investigator. ..
  36. Eliciting Patient Treatment Preferences for Osteoporosis
    Liana Fraenkel; Fiscal Year: 2008
    ..abstract_text> ..
  37. Growth hormone secretagogue MK-677 therapy in CKD and ESRD
    WARREN BOLTON; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  38. Tyrosine Kinase Pathways in Autoimmune Arthritis.
    Ricardo Paniagua; Fiscal Year: 2008
    ....
  39. derG Immunostimulant Prevention/Treatment of HSV Disease
    Daniel Zimmerman; Fiscal Year: 2003
    ..An integral part of the phase II program will be to further elucidate the target cells and mechanism of action of derG. ..
  40. Enhancement of methotrexate uptake in childhood ALL
    John McGuire; Fiscal Year: 2009
    ..If successful, this research could provide a way to increase the effectiveness of methotrexate, a key drug used in treating childhood acute lymphoblastic leukemia, and thus increase the cure rate in this disease. ..
  41. Antigen-specific CD8+ T cells and protective immunity to tuberculosis
    Samuel M Behar; Fiscal Year: 2010
    ..tuberculosis-specific immune response will also be determined. This proposal will directly assess how CFP10-specific CD8+ T cells contribute to host defense and how their function is modulated by immunity and disease. ..
  42. CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE
    Michael Roth; Fiscal Year: 2009
    ..It will also allow us to develop biologic markers and predictors of disease progression and to determine which patients would benefit most from treatment with cytotoxic therapy. ..
  43. Analysis of Genetic Susceptibility to Anterior Uveitis
    TAMMY MARTIN; Fiscal Year: 2009
    ..Specific Aim 3: To identify specific candidate gene mutations by using SNP marker analysis, by comparative DNA sequencing and by denaturing HPLC analysis. ..
  44. MS4A Family Members in Health and Disease
    Thomas Tedder; Fiscal Year: 2008
    ..abstract_text> ..
  45. Novel regulatory role of cryopyrin in inflammation
    Harold Hoffman; Fiscal Year: 2005
    ..abstract_text> ..
  46. MULTIDISCIPLINARY TRAINING GRANT - RHEUMATOLOGIC DISEASE
    Sherine Gabriel; Fiscal Year: 2005
    ..abstract_text> ..
  47. Clinical Research Development Program (RMI)
    Sherine Gabriel; Fiscal Year: 2004
    ....
  48. Strategies for Evaluating and Treating Early Synovitis
    David Pisetsky; Fiscal Year: 2004
    ..Three specific aims are proposed: 1) to develop a clinical trial to test the window-of-opportunity hypothesis; 2) to test recruitment of patients in a pilot study; and 3) to assess ethical issues of early intervention. ..
  49. CLINICAL RESEARCH TRAINING PROGRAM
    Sherine Gabriel; Fiscal Year: 2004
    ..Together, these characteristics will ensure its success. ..
  50. Why is Cardiac Risk Increased in Rheumatiod Arthritis
    Daniel Solomon; Fiscal Year: 2002
    ..ability to control for known cardiovascular risk factors, the extensive medication information allowing for us to explore key hypotheses regarding corticosteroid exposure, and the attempt to simultaneously control for disease severity ..
  51. IMMUNOLOGICAL BASIS OF SUSCEPTIBILITY TO TUBERCULOSIS
    Samuel Behar; Fiscal Year: 2003
    ..Aim 4. Characterize the immune response to tuberculosis in mouse models that simulate the abnormalities of cell mediated immunity typical of HIV/AIDS patients. ..
  52. Peptide Vaccine for Experimental Autoimmune Myocarditis
    Daniel Zimmerman; Fiscal Year: 2003
    ..The effects of J-My-1 administration on the presence and frequency of this cell type will be evaluated. Our goal is to demonstrate that the severity of EAM can be reduced by J-My-1 administration in animals with EAM. ..
  53. FAMILY STUDIES OF THE GENETICS OF ANKYLOSING SPONDYLITIS
    John Reveille; Fiscal Year: 2003
    ..abstract_text> ..
  54. COCAINE SMOKING EFFECTS ON LUNG IMMUNITY & HOST DEFENSE
    Michael Roth; Fiscal Year: 2006
    ..abstract_text> ..
  55. Randomized Controlled Testing of Osteoporosis Education
    Daniel Solomon; Fiscal Year: 2006
    ..A multi-disciplinary Training Advisory Board will review the applicants progress regularly to ensure that the proposed training goals are met. ..
  56. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
    ..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
  57. Cognitive Behavioral Determinants in Knee Replacement
    Maria Suarez Almazor; Fiscal Year: 2007
    ..The intervention will be based on cognitive behavioral strategies. ..
  58. TRIPTORELIN FOR OVARY PROTECTION IN CHILDHOOD LIPUS
    Hermine Brunner; Fiscal Year: 2007
    ..Abstract Not Provided ..
  59. Preschool Vision Screening in Primary Care Settings
    Alex Kemper; Fiscal Year: 2007
    ....
  60. MOLECULAR ANALYSIS OF B-LYMPHOCYTE RESTRICTED PROTEINS
    Thomas Tedder; Fiscal Year: 2002
    ..Determining how these B cell-restricted proteins regulate B cell function may also provide new methods for treatment of B cell malignancies, autoimmunity and immunodeficiency. ..
  61. Periodontal Assessment in RA Study (PARAS)
    Clifton Bingham; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  62. Physical Activity and Quality of Life in Multiple Sclerosis
    Robert Motl; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  63. Mayo Clinical Research Development Program (RMI)
    Sherine Gabriel; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  64. A Genetic Model of Uveitis
    TAMMY MARTIN; Fiscal Year: 2006
    ..Both transgenic mice and transgenic mice crossed with NOD2 knock-out mice will be studied. [unreadable] [unreadable] [unreadable]..
  65. CD83 Regulation of Lymphocyte Development and Function
    Thomas Tedder; Fiscal Year: 2007
    ..an important regulatory checkpoint for helper T cell development, understanding its function may provide mechanisms for modulating humoral immunity and for the treatment of immunodeficiency, autoimmunity and malignancies ..